The ‘Pinking’ of Viagra Culture
Drug Industry Efforts to Create and Repackage Sex Drugs for Women
Datos Bibliográficos
| ID | 18985451 |
|---|---|
| Autores | Heather Hartley (Portland State University, Oregon, USA, autor de correspondencia) |
| Año | 2006 |
| Volumen | 9 |
| Número | 3 |
| Páginas | 363-378 |
| Fecha de publicación | 2006-07-01 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | Sexualities (JOURNAL) |
| Identificadores de la revista | ISSN: 1363-4607 • E-ISSN: 1461-7382 |
| Editorial | SAGE Publications (PUBLISHER • US) |
| DOI | 10.1177/1363460706065058 |
| OpenAlex | W1965223920 |
| Idioma | EN |
| Citas recibidas | 21 |
| Referencias citadas | 20 |
This essay will describe how the success of Viagra stimulated drug companies to create a women's sexual condition comparable to erectile problems in men for which they could market new sex drugs to women. The heart of the article focuses on two interrelated aspects of Viagra culture playing out in drug industry efforts to create and expand a market for sex drugs for women: (1) the industry's ‘Hunt for the Pink Viagra’ to treat the ‘disease’ of female sexual dysfunction (FSD), and (2) the prescription and promotion of off-label uses of men's sex drugs to women. In order to contextualize these two trends, the article outlines key activities and actions that have enabled the drug industry to consolidate power and build capacity in this area, including: mass dissemination of estimates of disease prevalence; the institutionalization of FSD in academic circles, which includes strategic revision of disease definitions as well as the creation of a legitimized infrastructure for dissemination of supporting research and education; and public-relations stimulated mainstream media coverage. The article concludes with a consideration of the ongoing challenges to the medicalization of women's sexuality as well as to harmful corporate practices more broadly
Business · Erectile dysfunction · Human sexuality · Mainstream · Medical prescription · Medicalization · Pharmaceutical industry · Political science · Politics · Psychiatry · Public relations · Sociology · Gender Studies · Historical Studies on Reproduction, Gender, Health, and Societal Changes · Medicine · Pharmaceutical industry and healthcare · Sexuality, Behavior, and Technology · Pharmacology
Fluid Drugs
Femininities
The Internet’s impact on sexuality
Empowered, Handmaid, or Rejector? The Framing of Low Libido in Women according to Scholarly Investigations of Public Communication
Effects of Mindfulness Training on Body Awareness to Sexual Stimuli
Drogas fluidas
Pre-exposure prophylaxis for HIV in Brazil
How Did Erectile Dysfunction Become “Natural”? A Review of the Critical Social Scientific Literature on Medical Treatment for Male Sexual Dysfunction
Intimate tablets
What Is the Problem With Sexual Intimacy Following Intimate Partner Violence in the DSM -5
Making Sense in and of the Asexual Community
Potency, Hubris and Susceptibility
Sexual improvement as if your health depends on it
Contested psychiatric ontology and feminist critique
Dating and sexualities across the life course
Minding the body, sexing the brain
Factors shaping women's sexual satisfaction
Diferenças de gênero e medicalização da sexualidade na criação do diagnóstico das disfunções sexuais
Sexual Desire, Testosterone and Biomedical Interventions
The Social Construction of Illness
The Perils and Pleasures of Aging
Report of the International Consensus Development Conference on Female Sexual Dysfunction
The making of a disease
Sexual Dysfunction in the United States
Manufacturing Desire
Sexology and the pharmaceutical industry
Distress About Sex
The Medicalization of Female Sexual Dysfunction
Promising Liberation but Delivering Business as Usual
| Obras citantes distintas | 21 |
|---|---|
| Citas por año | 1,24 |
| Intervalo de citas | 2009 - 2023 (15) |
| Velocidad de citación | historical |
| Altamente citado | No |
| Tipos de cita | Neutras: 20 |